EXHIBIT 7

Patti Nemeth, M.D.

Page 1

UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF ILLINOIS

- - -

IN RE DEPAKOTE: :

RHEALYN ALEXANDER, :

et al., : No.

Plaintiffs, : 12-52-NJR-SCW

VS. :

ABBOTT LABORATORIES, :

INC.,

Defendant. :

DEPOSITION UNDER ORAL EXAMINATION OF PATTI NEMETH, M.D.

9:00 a.m.

Rio Rancho, New Mexico

- - -

REPORTED BY: DANA SREBRENICK, CRR, CLR

- - -

Golkow Technologies, Inc.

877.370.3377 ph | 917.591.5672 fax deps@golkow.com

Page 20 I'd like to look at the page that's 1 Q. 2 stamped number 9. 3 Α. Okay, yes. And if you could tell me what that is? 4 Ο. 5 Α. Okay. That was January 27th, 2004 and 6 prior to this phone call, she had had some 7 seizures and episodes and she wanted to know about 8 -- if she could have another baby, should she be 9 on Depakote, can she get pregnant, should she 10 reduce the Depakote? 11 And does that -- that leads me to 12 believe, and correct me if I'm wrong, does it lead 13 you to believe that she had some indication of 14 risks of using a drug like Depakote? 15 Α. That -- well, we certainly talked about 16 it when she came in, so she -- I agree with what 17 you just said. 18 Then I believe she came to see you, it's 19 Bates page 10, on February the 4th of 2004? 20 Α. Yes. 21 And can you tell me what happened at this 22 visit when you were treating her? 23 We discussed the various antiseizure 24 medicine. And she was aware that Depakote was 25 class D and I suggested that we try one of the

Patti Nemeth, M.D.

Page 21

- 1 others that was class C and that was Lamictal.
- 2 So at that point I wanted to -- since she
- 3 was not pregnant at this time, so I wanted to
- 4 slowly start to convert her over to see -- to
- 5 Lamictal and to get off Depakote.
- 6 Q. And can you tell me -- you noted here
- 7 that Depakote is class D. Can you tell me what
- 8 that means?
- 9 A. Yes. It indicates -- I think it's an FDA
- 10 level class, indicates that that drug has been
- 11 tested in animals, female animals in this case,
- 12 and shown to cause fetal harm, making it
- 13 suspicious that it would also cause harm to
- 14 humans, although no human studies were done.
- But my understanding of class D is that
- 16 the potential risks of the drugs -- drug may be
- 17 outweighed by -- do I have that right? The
- 18 benefit -- no, the benefit may outweigh the risks
- 19 of the drug.
- 20 Q. So just so we're clear, the benefits
- 21 outweigh the risks?
- 22 A. May -- the risks can be outweighed by the
- 23 benefits, yes.
- Q. I'm sorry. Are you saying the risks
- could outweigh the benefits of the drug?

Page 23 Well, certainly it's riskier than a class 1 Α. 2 C, and then within the class D, there may be some 3 differences. 4 BY MR. BROSS: 5 But it doesn't tell you about the actual 6 risk of using that drug? 7 MR. KLATT: Objection, form. 8 By itself, it doesn't, but my knowledge 9 is that -- that class D drugs can cause fetal risk 10 -- or fetal harm, I should say. 11 And you would base this knowledge and 12 information on the late -- well, strike that. 13 You would have based this on the 14 knowledge that you had at the time back in 2003? 15 Α. Yes. 16 Ο. 2004? 17 Reading my notes, I -- I did understand Α. 18 it. 19 And this would have been something you shared with Ms. Sansone? 20 21 Α. Yes. 22 And, again, what did you recommend at 23 this time for Ms. Sansone? 24 So we discussed the importance of being

on a seizure medicine while she was pregnant and

25

Page 24

- 1 I -- she wasn't pregnant at the time, so I told
- 2 her we had time to -- to switch to a category C
- 3 drug. And I gave her a program of how to increase
- 4 each week the Lamictal and decrease the Depakote,
- 5 my conversion schedule.
- 6 O. What's a conversion schedule?
- 7 A. Well, just that. So the first day you
- 8 start the Lamictal and you just add it to the
- 9 Depakote. The next week you bring -- you bring up
- 10 the Lamictal and bring down the Depakote. And the
- 11 next week you bring the Lamictal up further and
- 12 the Depakote down. So it can take four weeks,
- 13 eight weeks.
- 14 Q. And just because a drug's a class C drug,
- 15 that doesn't necessarily mean it's safe in
- 16 pregnancy?
- 17 A. Well, correct.
- 18 Q. Then the next record I see looks like
- 19 page 11, dated February the 10th?
- 20 A. Yes.
- 21 Q. And here what were you doing?
- 22 A. Well, she was on the conversion plan and
- 23 she had a seizure. And she told my staff that she
- 24 was on Depakote 750 twice a day and Lamictal 25
- 25 milligrams every other day. I was really going

Page 25

- 1 slow, it looks like.
- 2 So I told her to increase the Depakote
- 3 and leave the Lamictal and then we'll -- we would
- 4 try to increase it, the Lamictal, after checking
- 5 the levels in a couple of weeks.
- 6 Q. Then on page -- what we have marked as
- 7 page 13, there was another phone call dated March
- 8 the 8th?
- 9 A. Yes.
- 10 Q. Can you tell me about that call?
- 11 A. Yes. She described nausea, dry heaves,
- mood swings and she thought the Lamictal was
- 13 making her ill. And she indicated where we were
- on the conversion schedule. My feeling was --
- 15 based on what she told me was that she probably
- 16 wouldn't be able to tolerate Lamictal, and so I
- went back down on Lamictal and kept her on
- 18 Depakote.
- 19 Q. Then it looks like on page 15, May the
- 20 11th of 2004, another phone call?
- 21 A. Yes. She had a seizure. She called
- 22 because she had a seizure and described it as loss
- of consciousness, and when she came to, she was
- 24 exhausted and groggy. And later that evening, she
- 25 woke up in -- and thought she had been drooling

```
Page 122
 1
                      CERTIFICATION
 2
 3
 4
           I, DANA N. SREBRENICK, a Certified Court
 5
     Reporter for and within the State of New Mexico,
 6
     do hereby certify:
 7
           That the witness whose testimony as herein
 8
     set forth, was duly sworn by me; and that the
     within transcript is a true record of the
 9
10
     testimony given by said witness.
11
           I further certify that I am not related to
12
     any of the parties to this action by blood or
13
     marriage, and that I am in no way interested in
14
     the outcome of this matter.
15
           IN WITNESS WHEREOF, I have hereunto set my
     hand this 5th day of October 5, 2016.
16
17
18
19
           DANA N. SREBRENICK, CLR, CRR
20
2.1
22
23
2.4
25
```